A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF‐binding site distant from its epitope

Background: BO2C11 is a human monoclonal factor (F) VIII inhibitor. When bound to the C2 domain of FVIII, the Fab fragment of BO2C11 (FabBO2C11) buries a surface of C2 that contains residues participating in a binding site for von Willebrand factor (VWF). BO2C11 has thus been proposed to neutralize...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and haemostasis 2010-07, Vol.8 (7), p.1524-1531
Hauptverfasser: DIMITROV, J. D., ROUMENINA, L. T., PLANTIER, J.‐L., ANDRE, S., SABOULARD, D., MESLIER, Y., PLANCHAIS, C., JACQUEMIN, M., SAINT‐REMY, J.‐M., ATANASOV, B. P., KAVERI, S. V., LACROIX‐DESMAZES, S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1531
container_issue 7
container_start_page 1524
container_title Journal of thrombosis and haemostasis
container_volume 8
creator DIMITROV, J. D.
ROUMENINA, L. T.
PLANTIER, J.‐L.
ANDRE, S.
SABOULARD, D.
MESLIER, Y.
PLANCHAIS, C.
JACQUEMIN, M.
SAINT‐REMY, J.‐M.
ATANASOV, B. P.
KAVERI, S. V.
LACROIX‐DESMAZES, S.
description Background: BO2C11 is a human monoclonal factor (F) VIII inhibitor. When bound to the C2 domain of FVIII, the Fab fragment of BO2C11 (FabBO2C11) buries a surface of C2 that contains residues participating in a binding site for von Willebrand factor (VWF). BO2C11 has thus been proposed to neutralize FVIII by steric hindrance. Objectives: The BO2C11 epitope on C2 overlaps with residues located at the periphery of the putative VWF binding site; hence, most of the residues that constitute the VWF binding site on C2 and a3 remain accessible for VWF interaction following BO2C11/FVIII complex formation. We thus investigated the contribution of alternative molecular mechanisms to FVIII inactivation by BO2C11. Methods: Continuum electrostatic calculations were applied to the crystal structure of C2, free or FabBO2C11‐complexed. In silico predictions were confirmed by site‐directed mutagenesis and VWF‐binding assays of the mutated FVIII. Results: Binding of FabBO2C11 to C2 induced perturbations in the electrostatic potential of C2 and in the local electrostatic parameters of 18 charged residues in C2, which are distant from the BO2C11 epitope. Nine of the predicted electrostatic hotspots clustered on the VWF‐binding site of C2. Mutation of some of the predicted electrostatic hotspots has been associated with hemophilia A and reduced VWF binding in vitro. Conclusions: Inhibitors may neutralize FVIII by alteration of protein surface electrostatics at a long distance from their epitope. Perturbation of the electrostatic environment of C2, either upon binding by anti‐FVIII antibodies or consecutive to missense mutations in the F8 gene, may lead to hampered VWF binding and reduced FVIII residence time in circulation.
doi_str_mv 10.1111/j.1538-7836.2010.03878.x
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_746236247</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746236247</sourcerecordid><originalsourceid>FETCH-LOGICAL-p2968-485edd75e48ddcdcc6af0e9aeb821d8a30583af5d9975bb3b02640fc660454a83</originalsourceid><addsrcrecordid>eNo9kU1OwzAQhS0EoqVwBeQdqwQndhJnwaKqKA2qxKaUpeXEE-oqf8SOaHccgTNyEhJaOpsZzfv0Fu8hhD3iev3cb10voNyJOA1dn_RfQnnE3d0ZGp-E8_87pnSErozZEuLFgU8u0cgnNGKMxWNUT_GmK2WF5-skSbCuNjrVtm5xWauukBbMUTFdm8sMMBSQ2bY2VlqdGSwtlnj9Nv_5-k51pXT1jo22gJXuicrivK1LrK3B0PS2DVyji1wWBm6Oe4Je54-r2cJZvjwls-nSafw45A7jASgVBcC4UpnKslDmBGIJKfc9xSUlAacyD1QcR0Ga0pT4ISN5FoaEBUxyOkF3B9-mrT86MFaU2mRQFLKCujMiYqFPQ59FPXl7JLu0BCWaVpey3Yv_jHrg4QB86gL2J90jYuhCbMUQsxgiF0MX4q8LsRPPq8Vw0V_C3H5m</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>746236247</pqid></control><display><type>article</type><title>A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF‐binding site distant from its epitope</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>DIMITROV, J. D. ; ROUMENINA, L. T. ; PLANTIER, J.‐L. ; ANDRE, S. ; SABOULARD, D. ; MESLIER, Y. ; PLANCHAIS, C. ; JACQUEMIN, M. ; SAINT‐REMY, J.‐M. ; ATANASOV, B. P. ; KAVERI, S. V. ; LACROIX‐DESMAZES, S.</creator><creatorcontrib>DIMITROV, J. D. ; ROUMENINA, L. T. ; PLANTIER, J.‐L. ; ANDRE, S. ; SABOULARD, D. ; MESLIER, Y. ; PLANCHAIS, C. ; JACQUEMIN, M. ; SAINT‐REMY, J.‐M. ; ATANASOV, B. P. ; KAVERI, S. V. ; LACROIX‐DESMAZES, S.</creatorcontrib><description>Background: BO2C11 is a human monoclonal factor (F) VIII inhibitor. When bound to the C2 domain of FVIII, the Fab fragment of BO2C11 (FabBO2C11) buries a surface of C2 that contains residues participating in a binding site for von Willebrand factor (VWF). BO2C11 has thus been proposed to neutralize FVIII by steric hindrance. Objectives: The BO2C11 epitope on C2 overlaps with residues located at the periphery of the putative VWF binding site; hence, most of the residues that constitute the VWF binding site on C2 and a3 remain accessible for VWF interaction following BO2C11/FVIII complex formation. We thus investigated the contribution of alternative molecular mechanisms to FVIII inactivation by BO2C11. Methods: Continuum electrostatic calculations were applied to the crystal structure of C2, free or FabBO2C11‐complexed. In silico predictions were confirmed by site‐directed mutagenesis and VWF‐binding assays of the mutated FVIII. Results: Binding of FabBO2C11 to C2 induced perturbations in the electrostatic potential of C2 and in the local electrostatic parameters of 18 charged residues in C2, which are distant from the BO2C11 epitope. Nine of the predicted electrostatic hotspots clustered on the VWF‐binding site of C2. Mutation of some of the predicted electrostatic hotspots has been associated with hemophilia A and reduced VWF binding in vitro. Conclusions: Inhibitors may neutralize FVIII by alteration of protein surface electrostatics at a long distance from their epitope. Perturbation of the electrostatic environment of C2, either upon binding by anti‐FVIII antibodies or consecutive to missense mutations in the F8 gene, may lead to hampered VWF binding and reduced FVIII residence time in circulation.</description><identifier>ISSN: 1538-7933</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/j.1538-7836.2010.03878.x</identifier><identifier>PMID: 20374449</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - pharmacology ; Binding Sites - drug effects ; Epitopes - immunology ; factor VIII ; Factor VIII - antagonists &amp; inhibitors ; Factor VIII - chemistry ; Factor VIII - genetics ; Factor VIII - immunology ; FVIII inhibitors ; Hemophilia A ; Humans ; inhibitory mechanism ; Models, Molecular ; Mutagenesis, Site-Directed ; Mutation, Missense ; Static Electricity ; surface electrostatics ; von Willebrand Factor - metabolism</subject><ispartof>Journal of thrombosis and haemostasis, 2010-07, Vol.8 (7), p.1524-1531</ispartof><rights>2010 International Society on Thrombosis and Haemostasis</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20374449$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>DIMITROV, J. D.</creatorcontrib><creatorcontrib>ROUMENINA, L. T.</creatorcontrib><creatorcontrib>PLANTIER, J.‐L.</creatorcontrib><creatorcontrib>ANDRE, S.</creatorcontrib><creatorcontrib>SABOULARD, D.</creatorcontrib><creatorcontrib>MESLIER, Y.</creatorcontrib><creatorcontrib>PLANCHAIS, C.</creatorcontrib><creatorcontrib>JACQUEMIN, M.</creatorcontrib><creatorcontrib>SAINT‐REMY, J.‐M.</creatorcontrib><creatorcontrib>ATANASOV, B. P.</creatorcontrib><creatorcontrib>KAVERI, S. V.</creatorcontrib><creatorcontrib>LACROIX‐DESMAZES, S.</creatorcontrib><title>A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF‐binding site distant from its epitope</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Background: BO2C11 is a human monoclonal factor (F) VIII inhibitor. When bound to the C2 domain of FVIII, the Fab fragment of BO2C11 (FabBO2C11) buries a surface of C2 that contains residues participating in a binding site for von Willebrand factor (VWF). BO2C11 has thus been proposed to neutralize FVIII by steric hindrance. Objectives: The BO2C11 epitope on C2 overlaps with residues located at the periphery of the putative VWF binding site; hence, most of the residues that constitute the VWF binding site on C2 and a3 remain accessible for VWF interaction following BO2C11/FVIII complex formation. We thus investigated the contribution of alternative molecular mechanisms to FVIII inactivation by BO2C11. Methods: Continuum electrostatic calculations were applied to the crystal structure of C2, free or FabBO2C11‐complexed. In silico predictions were confirmed by site‐directed mutagenesis and VWF‐binding assays of the mutated FVIII. Results: Binding of FabBO2C11 to C2 induced perturbations in the electrostatic potential of C2 and in the local electrostatic parameters of 18 charged residues in C2, which are distant from the BO2C11 epitope. Nine of the predicted electrostatic hotspots clustered on the VWF‐binding site of C2. Mutation of some of the predicted electrostatic hotspots has been associated with hemophilia A and reduced VWF binding in vitro. Conclusions: Inhibitors may neutralize FVIII by alteration of protein surface electrostatics at a long distance from their epitope. Perturbation of the electrostatic environment of C2, either upon binding by anti‐FVIII antibodies or consecutive to missense mutations in the F8 gene, may lead to hampered VWF binding and reduced FVIII residence time in circulation.</description><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>Binding Sites - drug effects</subject><subject>Epitopes - immunology</subject><subject>factor VIII</subject><subject>Factor VIII - antagonists &amp; inhibitors</subject><subject>Factor VIII - chemistry</subject><subject>Factor VIII - genetics</subject><subject>Factor VIII - immunology</subject><subject>FVIII inhibitors</subject><subject>Hemophilia A</subject><subject>Humans</subject><subject>inhibitory mechanism</subject><subject>Models, Molecular</subject><subject>Mutagenesis, Site-Directed</subject><subject>Mutation, Missense</subject><subject>Static Electricity</subject><subject>surface electrostatics</subject><subject>von Willebrand Factor - metabolism</subject><issn>1538-7933</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kU1OwzAQhS0EoqVwBeQdqwQndhJnwaKqKA2qxKaUpeXEE-oqf8SOaHccgTNyEhJaOpsZzfv0Fu8hhD3iev3cb10voNyJOA1dn_RfQnnE3d0ZGp-E8_87pnSErozZEuLFgU8u0cgnNGKMxWNUT_GmK2WF5-skSbCuNjrVtm5xWauukBbMUTFdm8sMMBSQ2bY2VlqdGSwtlnj9Nv_5-k51pXT1jo22gJXuicrivK1LrK3B0PS2DVyji1wWBm6Oe4Je54-r2cJZvjwls-nSafw45A7jASgVBcC4UpnKslDmBGIJKfc9xSUlAacyD1QcR0Ga0pT4ISN5FoaEBUxyOkF3B9-mrT86MFaU2mRQFLKCujMiYqFPQ59FPXl7JLu0BCWaVpey3Yv_jHrg4QB86gL2J90jYuhCbMUQsxgiF0MX4q8LsRPPq8Vw0V_C3H5m</recordid><startdate>201007</startdate><enddate>201007</enddate><creator>DIMITROV, J. D.</creator><creator>ROUMENINA, L. T.</creator><creator>PLANTIER, J.‐L.</creator><creator>ANDRE, S.</creator><creator>SABOULARD, D.</creator><creator>MESLIER, Y.</creator><creator>PLANCHAIS, C.</creator><creator>JACQUEMIN, M.</creator><creator>SAINT‐REMY, J.‐M.</creator><creator>ATANASOV, B. P.</creator><creator>KAVERI, S. V.</creator><creator>LACROIX‐DESMAZES, S.</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7T5</scope><scope>H94</scope></search><sort><creationdate>201007</creationdate><title>A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF‐binding site distant from its epitope</title><author>DIMITROV, J. D. ; ROUMENINA, L. T. ; PLANTIER, J.‐L. ; ANDRE, S. ; SABOULARD, D. ; MESLIER, Y. ; PLANCHAIS, C. ; JACQUEMIN, M. ; SAINT‐REMY, J.‐M. ; ATANASOV, B. P. ; KAVERI, S. V. ; LACROIX‐DESMAZES, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p2968-485edd75e48ddcdcc6af0e9aeb821d8a30583af5d9975bb3b02640fc660454a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>Binding Sites - drug effects</topic><topic>Epitopes - immunology</topic><topic>factor VIII</topic><topic>Factor VIII - antagonists &amp; inhibitors</topic><topic>Factor VIII - chemistry</topic><topic>Factor VIII - genetics</topic><topic>Factor VIII - immunology</topic><topic>FVIII inhibitors</topic><topic>Hemophilia A</topic><topic>Humans</topic><topic>inhibitory mechanism</topic><topic>Models, Molecular</topic><topic>Mutagenesis, Site-Directed</topic><topic>Mutation, Missense</topic><topic>Static Electricity</topic><topic>surface electrostatics</topic><topic>von Willebrand Factor - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>DIMITROV, J. D.</creatorcontrib><creatorcontrib>ROUMENINA, L. T.</creatorcontrib><creatorcontrib>PLANTIER, J.‐L.</creatorcontrib><creatorcontrib>ANDRE, S.</creatorcontrib><creatorcontrib>SABOULARD, D.</creatorcontrib><creatorcontrib>MESLIER, Y.</creatorcontrib><creatorcontrib>PLANCHAIS, C.</creatorcontrib><creatorcontrib>JACQUEMIN, M.</creatorcontrib><creatorcontrib>SAINT‐REMY, J.‐M.</creatorcontrib><creatorcontrib>ATANASOV, B. P.</creatorcontrib><creatorcontrib>KAVERI, S. V.</creatorcontrib><creatorcontrib>LACROIX‐DESMAZES, S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>DIMITROV, J. D.</au><au>ROUMENINA, L. T.</au><au>PLANTIER, J.‐L.</au><au>ANDRE, S.</au><au>SABOULARD, D.</au><au>MESLIER, Y.</au><au>PLANCHAIS, C.</au><au>JACQUEMIN, M.</au><au>SAINT‐REMY, J.‐M.</au><au>ATANASOV, B. P.</au><au>KAVERI, S. V.</au><au>LACROIX‐DESMAZES, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF‐binding site distant from its epitope</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2010-07</date><risdate>2010</risdate><volume>8</volume><issue>7</issue><spage>1524</spage><epage>1531</epage><pages>1524-1531</pages><issn>1538-7933</issn><eissn>1538-7836</eissn><abstract>Background: BO2C11 is a human monoclonal factor (F) VIII inhibitor. When bound to the C2 domain of FVIII, the Fab fragment of BO2C11 (FabBO2C11) buries a surface of C2 that contains residues participating in a binding site for von Willebrand factor (VWF). BO2C11 has thus been proposed to neutralize FVIII by steric hindrance. Objectives: The BO2C11 epitope on C2 overlaps with residues located at the periphery of the putative VWF binding site; hence, most of the residues that constitute the VWF binding site on C2 and a3 remain accessible for VWF interaction following BO2C11/FVIII complex formation. We thus investigated the contribution of alternative molecular mechanisms to FVIII inactivation by BO2C11. Methods: Continuum electrostatic calculations were applied to the crystal structure of C2, free or FabBO2C11‐complexed. In silico predictions were confirmed by site‐directed mutagenesis and VWF‐binding assays of the mutated FVIII. Results: Binding of FabBO2C11 to C2 induced perturbations in the electrostatic potential of C2 and in the local electrostatic parameters of 18 charged residues in C2, which are distant from the BO2C11 epitope. Nine of the predicted electrostatic hotspots clustered on the VWF‐binding site of C2. Mutation of some of the predicted electrostatic hotspots has been associated with hemophilia A and reduced VWF binding in vitro. Conclusions: Inhibitors may neutralize FVIII by alteration of protein surface electrostatics at a long distance from their epitope. Perturbation of the electrostatic environment of C2, either upon binding by anti‐FVIII antibodies or consecutive to missense mutations in the F8 gene, may lead to hampered VWF binding and reduced FVIII residence time in circulation.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20374449</pmid><doi>10.1111/j.1538-7836.2010.03878.x</doi><tpages>8</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1538-7933
ispartof Journal of thrombosis and haemostasis, 2010-07, Vol.8 (7), p.1524-1531
issn 1538-7933
1538-7836
language eng
recordid cdi_proquest_miscellaneous_746236247
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Antibodies, Monoclonal - immunology
Antibodies, Monoclonal - pharmacology
Binding Sites - drug effects
Epitopes - immunology
factor VIII
Factor VIII - antagonists & inhibitors
Factor VIII - chemistry
Factor VIII - genetics
Factor VIII - immunology
FVIII inhibitors
Hemophilia A
Humans
inhibitory mechanism
Models, Molecular
Mutagenesis, Site-Directed
Mutation, Missense
Static Electricity
surface electrostatics
von Willebrand Factor - metabolism
title A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF‐binding site distant from its epitope
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T04%3A53%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20human%20FVIII%20inhibitor%20modulates%20FVIII%20surface%20electrostatics%20at%20a%20VWF%E2%80%90binding%20site%20distant%20from%20its%20epitope&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=DIMITROV,%20J.%20D.&rft.date=2010-07&rft.volume=8&rft.issue=7&rft.spage=1524&rft.epage=1531&rft.pages=1524-1531&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/j.1538-7836.2010.03878.x&rft_dat=%3Cproquest_pubme%3E746236247%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=746236247&rft_id=info:pmid/20374449&rfr_iscdi=true